Abstract
Introduction
Clinical N1 (cN1) disease of non-small cell lung cancer (NSCLC) represents the subset suggestive of ipsilateral hilar and/or intrapulmonary lymph node metastasis. [1] Although cN1 disease is considered to be locoregional, surgical resection often fails in curing cN1 patients. Mountain reported that the postoperative 5-year survival rates of clinical T1N1, T2N1, and T3N1 patients were 34%, 24%, and 9%, respectively. [2] One possible explanation for the disappointing outcome is that cN1 patients often have clinically occult mediastinal lymph node metastases (N2), which is a sign of systemic disease.
Contrast-enhanced computed tomography (CT) scan is the most widely available and most commonly used non-invasive method to evaluate lymph node status for NSCLC patients, in spite of the introduction of positron emission tomography (PET) scans. [3] Many studies have reported the diagnostic accuracy of CT scans for N2 disease. A meta-analysis of 20 studies with 3438 patients demonstrated that CT had 57% of sensitivity and 82% of specificity for mediastinal node staging. [4] We previously reported 17% of clinical N0 NSCLC patients had pN2 disease. [5] Although it is very likely that the cN1 patient cohort includes more clinically undetectable N2 patients, few reports have evaluated pathological stage distribution of CT-diagnosed clinical N1 NSCLC patients. [6] To reveal the problems in the current diagnostic standards of cN1 NSCLC, we retrospectively evaluated surgical and pathological results of this cohort. Furthermore, we attempted to identify clinical and radiological characteristics of cN1 patients to predict mediastinal lymph node metastases in order to help select patients who would benefit from additional lymph node staging modalities.
Methods

Patient population
We reviewed the medical records of 1782 consecutive NSCLC patients who underwent intended curative surgical resection at the National Cancer Center Hospital East, Chiba, Japan from January 1993 through June 2003. Among them, a total of 159 patients with cN1 disease were identified. Data collection and analyses were approved and the need for obtaining informed consent from each patient was waived by the institutional review board in March 2005. We excluded 16 patients from this study for the following reasons: 8 patients who underwent preoperative induction therapy, 3 patients who underwent limited resection without systemic hilar and mediastinal lymph node dissection, 3 patients who underwent mediastinoscopy to rule out cN2 disease, and 2 patients who had synchronous metastatic disease (M1). Subsequently, 143 (8%) patients were enrolled in this retrospective study. The clinical characteristics of these patients are shown in table 1. There were 114 men and 29 women with a median age of 64 years (range, 25 to 83). Eighty-five (59%) patients complained of at least one symptom on their first visit to our outpatient clinic. The most prevalent symptom was cough in 42 patients, followed by haemoptysis in 31 patients. Before surgery, all the patients underwent thorough staging with chest roentogenography, chest and upper abdominal contrast-enhanced CT, bone scintigraphy, and magnetic resonance imaging or CT scan of the whole brain. The most common T factor was T2 (61%), reflecting the mean tumour size on CT scans (4.6±1.9 cm [±, standard deviation]). Squamous cell carcinoma was the most frequent histology (48%, 69/143). Bronchoscopy was done in selected patients to evaluate cancer extension in the bronchial tree. We did not routinely use PET scan for preoperative staging. We did not perform mediastinoscopy or thoracoscopy for cN1 patients. All patients underwent anatomical lung resection (at least lobectomy) with systemic hilar and mediastinal lymph node dissection as described elsewhere. [7] The number of dissected lymph nodes ranged from 4 to 70, with a mean of 30. Resected specimens were examined histologically, and their histologic type was determined according to the World Health Organization International Histological Classification of Tumours. [8] The pathological stages were determined based on the TNM classification of the International Union Against Cancer. [1] After surgery, patients were scheduled to visit our outpatient clinic at 3 to 6 month intervals for 5 years. The median follow-up period was 5.1 years (range, 7 months to 11 years).
Preoperative evaluation and analysis of N1 status Dynamic incremental scanning was performed on X-Vigour or Aquilion CT equipment (Toshiba; Tokyo, Japan) after a bolus injection of 100 mL of contrast material using an automatic injector, and 10-mm thick contiguous CT sections were reconstructed. All CT films were interpreted by at least two experienced thoracic radiologists who were blinded to other clinical information. Clinical N1 disease status was diagnosed when one or more lymph nodes in the N1 region were larger than 1.0 cm in the shortest axis, in accordance with the general consensus of the upper size limit for normal mediastinal lymph nodes. The N1 node stations were designated according to the lymph node map by Naruke and coworkers [7] : number 10 hilar along the main bronchus, number 11 interlobar, number 12 lobar, number 13 segmental bronchial, and number 14 intrapulmonary lymph nodes. Since our series was obtained over a 10-year period and not evaluated by the identical CT equipments and radiologists, we retrospectively reviewed preoperative chest CT scans and confirmed all the 143 enrolled patients truly satisfied cN1 diagnosis criteria. During the review process, additional radiological findings were collected for the current study purpose. They included the presence or absence of atelectasis and obstruction pneumonia and the cN1 patterns. We defined two cN1 patterns according to the relationship between the main tumour and N1 node depicted on CT. We defined "continuous N1" as a N1 node directly involved by the main tumour, and "separate N1" as a N1 node separate from the main tumour (fig 1) . N1 node connected with the main tumour only by pre-existing normal bronchovascular structure was classified as separate N1.
Statistical analysis
We analyzed categorical variables by Pearson's χ 2 test. Survivals were estimated using the Kaplan-Meier method, and survival curves were compared by log-rank tests. The length of survival was defined as the interval between the day of surgical resection and the date of either death or the last follow-up. An observation was censored at the last follow-up when the patient was alive or lost to follow-up. Univariate logistic regression analysis was performed to identify factors predicting for pN2-3 disease among cN1 population. Multivariate logistic regression analysis was carried out by using significant predictors in univariate analysis to clarify which factor is associated with higher risk of pN2-3 disease. Cox proportional hazards regression analysis was used to determine the relationship between survival and pathological nodal status. Differences were considered to be statistically significant when the p value was less than 0.05. All statistical analyses were performed using software packages (JMP, release 5.0; SAS Institute Inc, Cary, NC, USA and GraphPad Prism, release 4.03; GraphPad Software Inc, San Diego, CA, USA).
Results
Diagnostic reliability of cN1 status by CT scans
The pathological lymph node status of the 143 cN1 patients was N0 in 33 (23%) patients, N1 in 67 (47%), N2 in 40 (28%), and N3 in 3 (2%). In 30% of cN1 patients (n = 43), lymph node status was upstaged to pN2-3. Among 40 cN1/pN2 patients, 6 (15%) had metastases in multiple N2 stations. The locations of N1 lymph node depicted on CT scans are shown in table 2. The interlobar (number 11) node was detected most frequently (81%), followed by the hilar (number 10) node in 24%. The lobar (number 12), segmental bronchial (number 13), and intrapulmonary (number 14) nodes were depicted in only 15 (10%) patients. Table 3 shows the relationship between preoperative clinico-radiological characteristics and proportion of pN2-3 disease among the cN1 NSCLC patients. In univariate logistic regression analysis, we found statistically significant associations between probability of pN2-3 disease and female gender (odds ration [ Table 4 ). Pathological N2-3 disease was found in 50% of adenocarcinoma patients and 42% of the patients with separate N1 pattern on CT. In 34 adenocarcinoma patients with separate N1 pattern, 18 (53%) had pN2-3 status. On the other hand, in 58 non-adenocarcinoma patients with continuous N1 pattern, only 7 (12%) had pN2-3 disease (Table 5) .
Predictors for pN2-3 disease among cN1 patients
Treatment for cN1 patients
As shown in table 1, it is remarkable that about a half of the enrolled cN1 patients underwent extensive lung resection greater than lobectomy; pneumonectomy was performed in 42 (29%) patients and bilobectomy in 35 (24%). Bronchoplastic procedures were performed in 16 (11%) patients. Pneumonectomy was done mainly for patients with squamous cell carcinoma (squamous cell carcinoma in 26 (62%), adenocarcinoma in 12 (29%), and adenosquamous carcinoma in 4 (9%), respectively). Radiotherapy was performed postoperatively in 7 patients: 6 for their positive surgical margins and one with pT1N1M0 moderately-differentiated squamous cell carcinoma for adjuvant purpose. Platinum-based adjuvant chemotherapy was given only in two cN1/pN2 patients, because it was not the standard of care in our practice until January 2004 when the International Adjuvant Lung Cancer Trial results were published. [9] Prognosis of cN1 patients During the follow-up period, 65 (45%) patients developed recurrence. Median time from resection to recurrence was 316 days (range, 11-2732). Table 6 shows number of patients with recurrence and their initial recurrence sites according to pathologic N status. The cN1/pN2-3 population developed approximately twice as many recurrent diseases as cN1/pN0-1 populations. Recurrent disease arising in the cN1/pN2-3 population were almost distant recurrences (29/32, 91%). Two cN1/pN2 patients who received adjuvant chemotherapy developed multiple distant recurrences and died at 2.7 and 8.3 years, respectively. The cumulative overall 1-, 3-, and 5-year survival rates of cN1 patients were 83%, 63%, and 55%, respectively, with a median survival time of 7.4 years (fig 2) . When we stratified the survival according to the pathological lymph node status, the cumulative overall 1-, 3-, and 5-year survival rates of cN1/pN0 patients (n = 33) were 88%, 75%, and 68%, and those of cN1/pN1 patients (n = 67) were 85%, 67%, and 60%, respectively. Patients with upstaged (pN2-3) nodal status (n = 43) showed significantly worse survival than pN0 and pN1 patients (p = 0.017 and 0.0068, respectively). Hazard ratio (HR) for pN2-3 disease relative to pN0 and pN1 were 2.19 (95% CI, 1.15 -4.38; p = 0.017) and 2.06 (95% CI, 1.20 -3.54; p = 0.0093), respectively. The cumulative overall 1-, 3-, and 5-year survival rates of cN1/pN2-3 patients were 67%, 44%, and 38%, respectively, with a median survival time of 2.7 years (fig 3) .
Discussion
Lymph node status is one of the most important determinants in diagnosing surgical respectability for NSCLC patients. [2] For patients with N0 and N1 status, the standard of care is local treatment, mostly surgical resection, whereas N2 and N3 patients are usually considered to be candidates for systemic therapy. [10] Since cN1 disease is a borderline subset for which different treatment strategies are considered, the accurate preoperative diagnosis of N1 status is essential. [6] Although overestimating a pN0 patient as cN1 does not alter treatment strategy, underestimating a pN2-3 patient as cN1 can result in an incorrect treatment strategy and thus should be avoided.
In our series, N1 status was correctly diagnosed in only 47% of CT-diagnosed cN1 population. Thirty percent of cN1 patients actually had pN2-3 disease, and 23% had pN0. Our results were almost consistent with those reported previously by Watanabe and colleagues. [6] They evaluated clinico-pathological correlation of nodal status for 135 cN1 patients diagnosed similarly to us, and reported that the pathological nodal status was pN0 in 19%, pN1 in 44%, and pN2-3 in 37%, respectively. [6] N1 diagnosis by contrast-enhanced CT is concluded to be inaccurate.
The high frequency of upstaging to pN2-3 among the cN1 population might be explained by the following. First, the majority of the CT-detected N1 nodes were located around the hilum. As shown in table 2, the enlargement of interlobar (number 11) and hilar (number 10) nodes were detected in 81% and 24% of our study population, respectively. However, lobar (number 12), segmental (number 13), and intrapulmonary (number 14) node involvement was pointed out in only 15 (10%) patients. Peripheral lymph nodes are usually small, and might be rarely enlarged more than 1 cm even when metastatic. Tumour cells in the N1 nodes located downstream in the pulmonary lymphatic system, i.e. the nodes around the hilum as compared to the peripheral nodes, are more likely to pass into the mediastinum. Secondly, some mediastinal nodes adjacent to the hilum might be misdiagnosed as N1. The anatomical border between the hilar (number 10) and tracheobronchial (number 4) or subcarinal (number 7) nodes is controversial, [7, 11, 12] and the diagnostic criteria for hilar nodes on CT scans have not yet been clearly established. In our series, among 34 patients with number 10 node enlargement on CT scans, 14 (41%) revealed metastatic nodes in the number 4 or 7 station. Consequently, CT-diagnosed N1 disease may represent "advanced" N1 disease that behaves like limited N2 disease.
The cN1/pN2-3 population in our series revealed significantly poor prognosis, as described in fig. 3 . It has not been established which the N2 disease optimal treatment is: surgery followed by adjuvant chemotherapy, induction therapy followed by resection, or chemoradiotherapy. In clinical practice, treatment may depend on physical characteristics and conditions of individual patients. The N2 disease detection before thoracotomy may change treatment strategy from primary surgery to other treatments. The high frequency and poor prognosis of cN1/pN2-3 disease population prompted us to identify clinical and radiological factors predicting occult N2 disease. Adenocarcinoma histology, the statistically significant predictor (p = 0.005), predicted pN2 disease in 50%. Separate N1 pattern on CT predicted pN2 in 42%, although it did not reach statistical significance (p = 0.066). When both factors were combined, pN2 status was predicted in 53%. Several authors have pointed out from a prognostic point of view that metastatic involvement of N1 node apart from the primary tumour should be distinguished from direct invasion. [13, 14] Separate N1 appearance on CT may represent distinct tumour metastases and may also predict more frequent occult mediastinal node metastases. Adenocarcinoma patients, especially with separate N1 pattern on CT, may need additional group.bmj.com on June 22, 2017 -Published by http://thorax.bmj.com/ Downloaded from imaging modalities to rule out N2 disease for appropriate treatment strategy. [6] Fluorodeoxyglucose-PET scan, which is based on tumour physiology, has a higher diagnostic accuracy than CT scan for mediastinal staging. A recent meta-analysis reported median sensitivity and specificity of 85% and 90% by PET scan (vs. 61% and 79%, respectively, for CT scan). [15] Integrated PET/CT, which combines the functional information of PET with the anatomic precision of CT, has been found to have an even higher diagnostic accuracy than either CT or dedicated PET, with a reported sensitivity of 89% and specificity of 94% and an overall diagnostic accuracy of 93%. [16] Adding PET or PET/CT study to CT might enable detecting occult N2 disease among cN1 population. However, negative PET findings dose not necessarily exclude N2 disease, and pathological confirmation of positive PET findings is commonly required to exclude false-positive findings. [17] In the current series, 13 (9%) of 143 cN1 patients underwent dedicated PET, and N2 disease were proven after surgery among 2 (15%) patients. Cerfolio et al recently reported that seven (41%) of 17 cN1 patients in whom N2 disease was ruled out by PET/CT were subsequently diagnosed as N2 by mediastinoscopy or endoscopic ultrasound with fine needle aspiration (EUS-FNA). [18] For CT-diagnosed N1 patients, PET and PET/CT imaging on N2 disease detection may be limited, and invasive biopsy modalities may need to be considered. Mediastinoscopy is considered to be the "gold standard" for examining whether there is N2 disease, and several authors concluded that all NSCLC patients considered for surgery should undergo mediastinoscopy irrespective of mediastinal lymph node sizes. [19, 20] However, we think the recommendation is excessive to be indicated for all cN1 patients. Mediastinoscopy is highly reliable with a sensitivity of 81% and a false negative rate of less than 10%. [21] But it is also costly, requires general anaesthesia, and has a complication rates ranging from 0.5 to 2.5%. [22, 23] Two predictive factors (adenocarcinoma histology and separate N1 status on CT scans) we demonstrated in the present study, might be helpful in selecting candidates for mediastinoscopy.
EUS-FNA and endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) have recently been reported as useful minimally invasive node biopsy modalities. Well-experienced endoscopists can access lymph nodes greater than 5 mm in size. [24, 25] Both procedures can be performed using moderate sedation with high sensitivity and specificity over 90%. [24] [25] [26] EUS-FNA also has an advantage of accessibility to subaortic (No. 5), paraesophageal (No. 8), and pulmonary ligament (No. 9) stations, which are not accessible by mediastinoscopy. By combining EUS-FNA and EBUS-TBNA, the majority of mediastinal lymph nodes could be accessible with minimal invasiveness. [27] EUS/EBUS biopsy might be a good alternative in detecting unsuspected N2 disease among cN1 population.
It is remarkable that more than a half of our cN1 patients underwent extensive resection of lung parenchyma: pneumonectomy in 29% and bilobectomy in 25% patients. Several investigators have conducted randomized trials comparing induction chemotherapy followed by surgery with surgery alone in stage IB or stage II NSCLC patients. Induction therapy is meaningful if it induces pathological downstaging, avoid extensive resection, and increase the chance of organ sparing surgery. However, recent multicenter phase III study by the French Thoracic Group targeting early-stage NSCLC including cN1 diseases could not significantly decrease overall pneumonectomy rate: 55.7% in surgery alone vs. 48.6% in induction chemotherapy followed by surgery groups (p = 0.30). [28] Further studies are necessary to clarify the role of neoadjuvant chemotherapy for cN1 patients. In the current standard, we have to evaluate cN1 patients whether they have enough cardiopulmonary reserve tolerable to extensive lung resection. [6] In conclusion, cN1 diagnosis by CT, the current standard staging modality for NSCLC, is not satisfactorily accurate. About 30% of cN1 patients had pN2-3 disease, and they might have benefited better from treatment strategy other than primary surgical resection if N2 status was proven before thoracotomy. Clinical N1 patients, especially with adenocarcinoma and possibly with separate N1 appearance on CT, should be considered to undergo additional invasive node biopsy modalities, including mediastinoscopy. Because extensive lung resection is often required for cN1 patients, careful cardiopulmonary function examination is needed to reduce perioperative complications. Adenocarcinoma and continuous N1 on CT 45%
Non-adenocarcinoma and separate N1 on CT 29%
Non-adenocarcinoma and continuous N1 on CT 12%
CT, computed tomography.
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Figure 2
Survival curve of patients with cN1 disease (n = 143). The 1-, 3-, and 5-year cumulative overall survivals were 83%, 63%, and 55%, respectively.
Figure 3
Survival curves of patients according to pathological N status. There was no statistically significant difference between pN0 and pN1 groups (p = 0.824, log-rank test). Patients with pN2-3 disease showed significantly worse survival than pN0 and pN1 groups (p = 0.017 and 0.0068, respectively, log-rank test). Five-year survival rates for pN0, pN1, and pN2-3 disease were 68%, 60%, and 38%, respectively. Hazard ratio (HR) with 95% confidence interval (CI) and median survival (MS) for each pathologic status are shown.
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